secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001274737-22-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q1 revenue $10.4M, net loss widens to $10.3M; raises FY 2022 guidance
----------------------------------------------------------------------------

- Q1 testing revenue $10.4M (flat YoY); total revenue $10.4M vs $10.6M in Q1 2021.
- Net loss $10.3M ($0.84 loss per share) vs $6.2M loss a year ago; gross margin fell to 44% from 55.5%.
- AVISE CTD test volume 30,903 (+6.5% YoY); record 2,175 ordering healthcare providers and 761 adopters.
- FY 2022 revenue guidance raised to $53-55M from $51-53M; cash $89.8M at quarter end.
- AMA issued PLA code for AVISE Lupus; Centene/WellCare in-network effective June 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/0001274737-22-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/exdx-20220511.htm
  HTML page:      https://secwatch.observer/filing/0001274737-22-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer